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The genetic architecture of blood pressure (BP) now includes more
than 30 genes, with rare mutations resulting in inherited forms of
hypertension or hypotension, and 1477 common single-nucleotide
polymorphisms (SNPs). These signify the heterogeneity of the BP
phenotype and support the mosaic theory of hypertension. The ma-
jority of monogenic syndromes involve the renin-angiotensin-
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L’architecture genetique de la pression arterielle (PA) comprend
maintenant plus de 30 gènes, avec des mutations rares entraînant des
formes hereditaires d’hypertension ou d’hypotension et 1 477 poly-
morphismes d’un seul nucleotide (PSN) courants. Tout cela demontre
l’heterogeneite du phenotype de la PA et soutient la theorie
« mosaïque » de l’hypertension. La majorite des syndromes lies aux
maladies monogeniques impliquent le système renine-angiotensine-
aldosterone et la voie des glucocorticoïdes via les glandes surrenales,
tandis qu’une plus petite fraction est due à de rares tumeursPage’s “mosaic theory” of hypertension posited that essential
hypertension (HTN) is not a single disease, but several
different diseases with different origins and developmentdall
causing HTN and its consequences.1 The mosaic of causes of
hypertension, if it exists for essential hypertension, needs
elucidation because it potentially opens new avenues for
stratification, new drug development, and precision medicine.
Blood pressure (BP) genomics has been one of the most
challenging research areas, primarily because the inherent
variability of BP and measurement errors (both human and
instrument related) substantially dilute the statistical power of
any discovery study. In this review, we leverage the current
catalogue of polygenic variants and monogenic variants asso-
ciated with BP regulation along with phenome-wide studies to
determine whether there is evidence for the mosaic theory,
and we explore potential translational aspects that underlie
different HTN subtypes.Monogenic Syndromes
There is evidence from monogenic forms of HTN that
they are caused by specific pathways perturbed by rare causal
mutations in single genes resulting in an early and severe BPphenotype.2 The monogenic forms are the most successful
examples of gene mapping, with mutations in more than 31
genes now linked to perturbed gene function and BP dysre-
gulation, enhancing our understanding of both the mecha-
nisms and the treatment of HTN. Molecular and clinical
details of monogenic syndromes have been reviewed in detail
recently, and we refer to the reader to these articles.2,3 Table 1
and Figure 1 summarise the monogenic syndromes, their
causal genes, mechanisms, and management. Different
monogenic syndromes all present with the same BP pheno-
type but are essentially separate diseases differentiated by
additional clinical or laboratory characteristics and the causa-
tive genetic mutation. Although monogenic forms of HTN
account for a small fraction of the public health burden of
hypertension, studies of monogenic syndromes have estab-
lished the genetic basis for the “known knowns” of BP
regulation. These are major pathways of BP regulation, cen-
tred on sodium balance and the renin-angiotensin-aldosterone
system, originally inferred from physiological studies that led
to the development of almost all of the commonly used
antihypertensive drugs.4 For example, one of the most effec-
tive drugs for HTN is spironolactone, which antagonises the
effect of aldosterone. It was discovered in 1957 and has been
used in clinical practice since 1959. The first case of familial
primary aldosteronism was described in 1966 with the dis-
covery of the causal chimeric mutation by Lifton et al.5 in
1992, 25 years later. Spironolactone, was recently shown to be
overwhelmingly the most effective drug treatment for resistant
HTN in the PATHWAY-2 randomised controlled trial.6
Interestingly, somatic gain-of-function mutations inll rights reserved.
Somatic mutations in genes coding for ion channels (KCNJ5 and
CACNA1D) and adenosine triphosphatases (ATP1A1 and ATP2B3)
highlight the central role of calcium signalling in autonomous aldo-
sterone production by the adrenal gland. The per-SNP BP effect is
small for SNPs according to genome-wide association studies (GWAS),
and all of the GWAS-identified BP SNPs explain w 27% of the 30%-
50% estimated heritability of BP. Uromodulin is a novel pathway
identified by GWAS, and it has now progressed to a genotype-directed
clinical trial. The majority of the GWAS-identified BP SNPs show
pleiotropic associations, and unravelling those signals and underpin-
ning biological pathways offers potential opportunities for drug repur-
posing. The GWAS signals are predominantly from Europe-centric
studies with other ancestries underrepresented, however, limiting the
generalisability of the findings. In this review, we leverage the bur-
geoning list of polygenic and monogenic variants associated with BP
regulation along with phenome-wide studies in the context of the
mosaic theory of hypertension, and we explore potential translational
aspects that underlie different hypertension subtypes.
neuroendocrines des glandes surrenales et des paraganglions sym-
pathiques et parasympathiques. Des mutations somatiques dans les
gènes codant les canaux ioniques (KCNJ5 et CACNA1D) et les
adenosine triphosphatases (ATP1A1 et ATP2B3) mettent en evidence
le rôle central de la signalisation du calcium dans la production
autonome d’aldosterone par la glande surrenale. L’effet de PSN lies à
la PA est faible pour les PSN identifies dans les etudes d’association
pangenomique (EAP), et tous les PSN de la PA identifies par EAP
expliquent w 27 % des 30 %-50 % d’heritabilite estimee de la PA.
L’uromoduline represente une nouvelle voie de signalisation identifiee
par les EAP, et elle fait desormais l’objet d’un essai clinique base sur le
genotype. La majorite des PSN lies à la PA identifies par des EAP
presentent des associations pleiotropes, et l’elucidation de ces signaux
et des voies biologiques sous-jacentes offre des possibilites poten-
tielles de reorientation de medicaments. Les donnees des EAP pro-
viennent principalement d’etudes de populations d’Europe, tandis que
les autres ascendances y sont sous-representees, ce qui limite la
generalisation des resultats. Dans cette revue de litterature, nous nous
appuyons sur la liste emergente des variants polygeniques et
monogeniques associees à la regulation de la PA ainsi que sur des
etudes à l’echelle du phenome dans le contexte de la theorie
« mosaïque » de l’hypertension, et nous explorons les aspects trans-
lationnels potentiels qui sous-tendent differents sous-types
d’hypertension.
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Hypertension Genomics and Mosaic Theory(KCNJ5) account for 40% of patients with an aldosterone-
producing adenoma, whereas 7% are due to mutations in
the a-subunit of Naþ-Kþ-adenosine triphosphatase (ATPase;
ATP1A1), plasma membrane Ca2þ-ATPase (ATP2B3), and
L-type Ca2þ channel CaV1.3 (CACNA1D).3 Mutations in
these genes are less frequent in inherited cases of primary
hyperaldosteronism and raises the possibility that HTN could
be due to a multiplicity of uncommon variants.3 The majority
of monogenic syndromes involve the renin-angiotensin-
aldosterone system and the adrenal glucocorticoid pathway
with treatment directed toward ultimately reducing aldoste-
rone and angiotensin and increasing Naþ excretion (Table 1).
A smaller fraction of monogenic HTN syndromes are due to
rare neuroendocrine tumours of the adrenal glands and the
sympathetic and parasympathetic paraganglia: pheochromo-
cytomas (PCCs) and paragangliomas (Table 1). Autosomal
hypertension with type E brachydactyly is not related to salt
reabsorption but due to mutation in the PDE3A gene
resulting in enhanced activity of PDE3A leading to increased
neointimal proliferation and remodelling of the arteries and
neurovascular structures.7
Although the rare monogenic syndrome may not have
significant direct public health impact, the indirect global
influence of drugs targeting those specific pathways among
those with essential HTN is substantial. It is in this context
that the potential value of the global efforts to discover the
genetic basis of essential or polygenic HTN needs to be
considered. Thus, monogenic syndromes fulfil Page’s mosaic
theory of HTN, albeit in a smaller subset of all hypertensive
individuals.Essential Hypertension
It logically follows that essential HTN may be a forme
fruste of monogenic HTN, with minor variations in themonogenic genes leading to milder and later-onset HTN.
Consequently, they may exhibit an underlying mosaic pattern.
There are indications that this may be a possibilitydfor
example, individuals of African ancestry tend to have a salt-
sensitive form of HTN,8 in contrast to individuals of Euro-
pean ancestry; somatic mutations causing hyper-
aldosteronism9 result in another subset of HTN. However,
beyond these 2 examples, it remains to be established if
essential HTN is a scaled-up mosaic form of monogenic
HTN.
Beyond the evidence from monogenic forms of HTN,
there are multiple lines of observational evidence suggesting
that BP has a genetic component. 1) Family and twin studies
have established that BP heritability ranges from 15% to 40%
for clinic systolic blood pressure (SBP), and from 15% to 30%
for clinic diastolic blood pressure (DBP); for ambulatory BP
(sleep), heritability was 69% and 51% for SBP and DBP,
respectively.10,11 2) The risk of developing HTN is signifi-
cantly increased in individuals with 1 or 2 hypertensive par-
ents,12 and monozygotic twins show higher BP correlations
than dizygotic twins.13 And 3) in the burst of discovery in the
genome-wide era, the search for common genetic variants
underlying BP is based on genome-wide association studies
(GWAS) which are hypothesis-generating studies that scan the
entire genome to find associations between genetic variants
(typically single-nucleotide polymorphisms [SNPs]) and a
phenotype. The first GWAS of HTN was entirely negative,
leading many to question if BP and HTN was genetically
tractable or if its genetic component was trivial.14 However,
since 2007, a series of sequential GWAS of BP and HTN with
sample sizes exponentially increasing to the latest study
involving 1 million subjects have identified more than 1477
SNPs associated with BP traits explaining about 27% of the
30%-50% estimated heritability of BP.2,15 All of these sup-
port a multifactorial polygenic basis for BP regulation and
Table 1. Monogenic syndromes of blood pressure dysregulation with causal genes, key features and treatment
Syndrome Gene Mechanism Key features Treatment
11b-Hydroxylase deficiency CYP11B1 Group of autosomal recessive disorders that
impair cortisol biogenesis with consequent
overproduction of corticotropin-releasing
hormone and ACTH and adrenal gland
hyperplasia. This leads to either hypotension
or hypertension.
Neonatal onset. Virilisation, short
stature, suppressed aldosterone and
renin.
Glucocorticoid therapy
17a-Hydroxylase deficiency CYP17A1 Hypertension, hypokalemic alkalosis.
Increased ACTH and follicle-
stimulating hormone. Absent sexual
maturation.
Glucocorticoid therapy, potassium-
sparing diuretics
21-Hydroxylase deficiency CYP21A2 Short stature, decreased fertility,
hirsutism. Salt wasting associated
with poor feeding, weight loss,
dehydration, and vomiting in babies.
Glucocorticoid therapy
3b-Hydroxysteroid dehydrogenase HSD3B2 Primary hypoadrenalism with
virilisation in females and
undervirilisation in males. Severe
form presents in infancy with salt
wasting and adrenal crisis.
Glucocorticoid therapy
Apparent mineralocorticoid excess
(AME)
HSD11B2 11b-Hydroxysteroid dehydrogenase
(HSD11B2) activity is reduced or absent.
This results in failure of cortisol conversion
to cortisone, leading to inappropriate
activation of the MR by cortisol and
hypertension.
Increased plasma ACTH. Increased
urinary cortisol-cortisone ratio. Low
plasma renin and aldosterone.
Low-sodium diet and spironolactone
Bartter syndrome CLCNKA
CLCNKB
KCNJ1
MAGED2
SLC12A1
Mutations in the SLC12A1 gene cause type I,
KCNJ1 type II, CLCNKB type III, and
BSND or a combination of mutations in the
CLCNKA and CLCNKB genes type IV.
Bartter syndrome results from defective salt
reabsorption in the thick ascending limb of
loop of Henle.
Low blood pressure. Impaired chloride
reabsorption in the thick ascending
loop of Henle leads to impaired
sodium reabsorption. Hypokalemic
metabolic alkalosis. Increased plasma
renin and aldosterone.
Potassium supplementation and use of
cyclooxygenase inhibitors,
angiotensin-converting enzyme
inhibitors, and potassium-sparing
diuretics.
Familial hyperaldosteronism (FH I) CYP11B1
CYP11B2
Hypertension caused by ACTH-driven
aldosterone secretion. A chimeric fusion
protein with the 50 regulatory sequences of
11b-hydroxylase (CYP11B1) (which confers
ACTH responsiveness) and the 30 coding
sequence of aldosterone synthase
(CYP11B2) results in ACTH becoming the
main controller for aldosterone secretion
instead of angiotensin II or potassium.
Plasma and urinary aldosterone
responsive to ACTH;
dexamethasone suppressible within
48 hours. Increased aldosterone and
low renin.
Dexamethasone
Familial hyperaldosteronism (FH II) Linkage to Chr 7p22,
KCNJ5
Unknown mechanism. Missense mutations in
KCNJ5 have been identified in rare cases.
May present either as an APA, bilateral
adrenal hyperaldosteronism (BAH),
or both. Fatigue, and muscle
weakness. Hypokalemia seen in
25% of patients.
Adrenalectomy is performed in case of
APA, medical therapy with
aldosterone antagonists in case of
BAH.
Gitelman syndrome SLC12A3
CLCNKB
Loss-of-function mutations in either NCC
encoded by SLC12A3 or CLCNKB lead to
decreased NaCl reabsorption in the distal
convoluted tubule, resulting in hypovolemia
and activation of the renin-angiotensin-
aldosterone system.
Low blood pressure. Increased plasma
renin. Renal potassium and
magnesium wasting.
Oral potassium and magnesium
supplementation with adequate salt
and water.
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Hypertension and brachydactyly
syndrome
PDE3A Mutations in PDE3A increase protein kinase A
emediated PDE3A phosphorylation,
increased cAMP hydrolysis and lowered
cAMP levels. This results in a gain of
function in PDE3A activity. The increase in
cAMP hydrolysis causes reduced levels of
cAMP levels in vascular smooth muscle cells
which, in turn, increases neointimal
proliferation and remodelling of the arteries
and neurovascular structures.
Brachydactyly type E, short phalanges,
short metacarpals
Possible role for PDE3 inhibition
Hypertension exacerbation in
pregnancy
NR3C2 Heterozygous mutation of the MR leads to
altered nuclear receptor ligand selectivity
and activation. Steroid hormones, such as
progesterone, have increased affinity for the
MR, leading to enhanced activation of
mineralocorticoid signalling cascades
(increases in ENaC and Na/Keadenosine
triphosphatase activity) that increase Naþ
reabsorption and Kþ secretion.
Low renin, low aldosterone,
hypokalemia. Progesterone and
other steroids lacking 21-hydroxyl
groups, normally MR antagonists,
becoming potent agonists.
Spironolactone contraindicated;
sodium chloride treatment. Delivery
of the foetus ameliorates
hypertension.
Liddle syndrome SCNN1B
SCNN1G
Autosomal dominant. Caused by heterozygous
mutations in SCNN1B or SCNN1G that
results in truncated C-terminus on either the
beta or gamma subunits of ENaC, removing
a binding site for NEDD-4. This results in
Constitutive activation of ENaC.
Salt-sensitive hypertension that
develops early in childhood. Low
plasma renin and aldosterone.
Hypokalemia.
Low sodium diet. Amiloride or
triamterence.
Multiple endocrine neoplasia, type IIA
(MEN2 syndrome)
RET Gain-of-function mutations of RET causes
MEN2 syndrome because normal
development of the kidneys and the
sympathetic, parasympathetic, and enteric
nervous system is dependent on RET.
Associated with multiple endocrine
neoplasms, including medullary
thyroid carcinoma,
pheochromocytoma, and
parathyroid adenomas
Alpha adrenergic blockers for
pheochromocytoma
Paragangliomas (PGL1-5) SDHA
SDHAF2
SDHB
SDHC
SDHD
SDH is a mitochondrial enzyme complex
consisting of four subunits: SDHA, SDHB,
SDHC, and SDHD involved in the
tricarboxylic acid cycle. The SDHx genes are
thought to function as classical tumour
suppressors, and mutations in any of the
SDHx genes abolishes SDH enzyme activity
and protein expression.
Multiple catecholamine-secreting
paragangliomas and
pheochromocytomas
Surgery, adrenergic blockers (alpha-
blockade followed by beta-blockade)
Pseudohypoaldosteronism (PHA II;
Gordon syndrome)
CUL3
KLHL3
NR3C2
WNK1
WNK4
Autosomal dominant. Mutant WNK1 results
in activation of SPAK, leading to enhanced
phosphorylation of NCC, increased NaCl
reabsorption and hypertension.
Overexpression of WNK1 can inhibit
WNK4 activity, further promoting
additional NCC phosphorylation and NaCl
reabsorption. Mutations in WNK4 disrupts
its binding to KLHL3, leading to increased
levels of WNK4 and hypertension. CUL3
and KLHL3 mutations disrupt proteolytic
degradation of the WNKs leading to
increased levels of WNK4.
Hypertension, hyperkalemia,
hyperchloremic metabolic acidosis
Thiazide diuretics, prostaglandin
inhibitors, alkalising agents, and
potassium-binding resins. Naþ- and
Kþ-restricted diet.
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Volume 36 2020HTNdthe Pickering argument from the 1950s Platt-
Pickering debate.16
Novel pathways from GWAS
Despite the plethora of common variants arising from
GWAS, the biggest challenge has been linking these variants
to a causal mechanism in the BP regulatory pathway. The
main reason for this is because GWAS SNPs are selected for
screening the genome based on linkage-disequilibrium pat-
terns, and this results in the majority of the signals being in
noncoding or intergenic regions. Nevertheless, there are ex-
amples of the value of GWAS in identification of novel
pathways of BP regulation point to potential subgroups with
common underlying pathways that may offer avenues for
targeted screening or therapy. We start with 2 SNPs (near
UMOD and PHACTR1/EDN1 genes) that have identified
novel pathways with early translational potential because they
involve gene products that are the targets for licensed drugs.
Then we look at pharmacogenetic interactions that validate
pathways targeted by current antihypertensive drugs and
explore opportunities for repurposing drugs or tailoring
treatment.
Uromodulin. A GWAS of BP extremes17 identified a 50-
promoter SNP, rs13333226, near the uromodulin gene
(UMOD) which is associated with BP and uromodulin
excretion. UMOD is almost exclusively expressed in the thick
ascending limb of the loop of Henle in the kidney, where
25% of the filtered Naþ is reabsorbed, pointing to a novel
sodium-based BP pathway. A potential interaction between
uromodulin and the main sodium transporter, NKCC2, in
the thick ascending limb of the loop of Henle was established
with transgenic mice experiments.18,19 In Umod-knockout
mice, NKCC2 shows reduced cotransporter activity with
consequent greater sodium excretion and a 20 mm Hg lower
BP compared with wild-type mice.18 The role of NKCC2 was
further established by Trudu et al.,19 who showed in both
mice overexpressing Umod and hypertensive individuals ho-
mozygous for the UMOD increasing allele that the NKCC2
antagonist furosemide had a greater natriuretic and hypoten-
sive effect. This result is currently being tested in a clinical
trial (ClinicalTrials.gov Identifier: NCT03354897) to repo-
sition loop diuretics in the HTN care pathway.
PHACTR1. An intronic SNP in the phosphatase and actin
regulatory protein 1 (PHACTR1) gene associated with
increased risk of coronary artery disease (CAD) and coronary
calcification and decreased risk of migraine headache, cervical
artery dissection, fibromuscular dysplasia, and HTN.20,21
Functional analysis of this variant indicated that it is a distal
regulator of endothelin (ET) 1 (EDN1), a gene located 600 kb
upstream of PHACTR1.20 Thus, this functional SNP may
potentially be associated with a lifetime’s exposure of at least
20% higher ET-1 precursor plasma levels, but this requires
more validation.20,22 EDN1 causes vasoconstriction and cell
proliferation through activation of ETA receptors (EDNRA)
on vascular smooth muscle cells and vasodilatation via release
of nitric oxide and prostacyclin (PGI2) through activation of
ETB receptors (EDNRB). Endothelin receptor antagonists
show BP-lowering properties with both ETA-selective and
Figure 1. Pathways in the circulatory, endocrine, and neurologic systems that are associated with monogenic forms of hypertension. Causal
monogenic genes and their syndromes are described in Table 1.
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Hypertension Genomics and Mosaic Theorynonselective drugs (bosentan, darusentan).23,24 However, ET
receptor antagonists did not gain traction as antihypertensive
agents because bosentan resulted in liver dysfunction and fluid
retention and darusentan did not meet its prespecifiedcoprimary end points. A new phase III trial, the PRECISION
study (ClinicalTrials.gov Identifier: NCT02603809) is
currently underway to test the efficacy of aprocitentan in
resistant hypertension.23,24 Endothelin receptor antagonists
Figure 2. Word cloud generated from all of the genome-wide association studieseidentified blood pressure (BP) single-nucleotide polymorphism
(SNP) associations with non-BP traits with a P value threshold of 58  105. The size of the words indicates the weight based on the number of
independent BP SNPs associated with each phenotype.
700 Canadian Journal of Cardiology
Volume 36 2020are now licensed for the treatment of pulmonary HTN.24 In
addition, a genotype-directed use of endothelin antagonists for
nonobstructive CAD may offer a solution for targeted treat-
ment (ClinicalTrials.gov Identifier: NCT04097314).Pleiotropy
Pleiotropy occurs when a given genetic locus (SNP) in-
fluences 2 or more different phenotypes or traits. Phenome-
wide association studies (PheWAS) can identify statistical
associations between a single variant and multiple phenotypes
and thus reveal pleiotropic associations. PheWAS are usually
carried out with the use of a wide range of phenotype data
from electronic health records, epidemiologic studies, and
clinical trials. Whereas GWAS typically investigates a single
phenotype at a time, PheWAS identify all of the traits asso-
ciated with a genetic variant. With near ubiquitous availability
of genome-wide genotyping in most large epidemiologic co-
horts and the emergence of biobanks, there is potential to
identify pleiotropic SNPs to improve our understanding of the
biological functions of a GWAS SNP or identify concealed
pathophysiologic connections between traits previously
considered as distinct. A look-up of all the 1477 BP SNPs in
the GWAS catalogue and PhenoScanner25,26 using a P value
threshold of 5  105 showed a range of significantly asso-
ciated traits. The pleiotropic traits are summarised in a word
cloud (Fig. 2), where the size of the words in the word cloud
indicates the weights based on the number of independent BP
SNPs associated with each phenotype. There is considerable
overlap of BP SNPs across traits that predispose to or correlate
with type 2 diabetes mellitus (T2DM). This suggests that the
co-occurrence of T2DM and HTN may manifest through
shared genetic factors and shared pathways. However,
detecting an independent BP effect on T2DM causation, even
if it exists, may be challenging. This is highlighted by 2 recent
studies that tried to establish a causal effect of BP on T2DM.
One study used 28 SNPs associated with T2DM and showed
that a 1 mm Hg rise in genetically determined SBP wascausally associated with a 2% increased risk of hypertension.27
However, a more recent bidirectional mendelian random-
isation study of UK Biobank participants, using a larger SNP
set of 134 T2DM SNPs and 233 BP SNPs, suggested that
T2DM may causally affect HTN, whereas the relationship
from HTN to T2DM is unlikely to be causal.28 Nevertheless,
genetics provides support for observed correlation between
T2DM and HTN and the presence of shared pathways raises
the possibility of combined treatment for both. The newer
SGLT2 inhibitors with dual effects on both glycemic control
and BP are a fortuitous example of a single drug with joint
effects on BP and glycemia and support investigation of shared
pathways to develop novel therapies for both conditions.29GWAS and Pharmacogenomics
The goal of genomics is to enable precision medicine
through a greater understanding of molecular pathways that
regulate BP, which can inform new drug development, per-
sonalisation of treatment, and ultimately lead to a new tax-
onomy of HTN.4 But there are significant challenges in
realising this goal. Current treatments of HTN have not seen
any new drug approval for more than 2 decades, mainly owing
to the view that current HTN management is well served by
the existing set of drug classes available. Tailoring of therapy
has not progressed beyond considering self-reported African
ancestry and serum renin levels.30,31
Linking all of the GWAS BP variants mapped to genes to the
DrugBank32 and Comparative Toxicogenomics Database33
shows that all of the major antihypertensive drug classes are
captured by pharmacogenetic interaction with these GWAS
loci (Fig. 3). Although this may simply reflect the fact that the
putative published genes mapped toGWAS SNPs were selected
for plausible BP effect, this raises the possibility of exploring
other genes in the region of GWAS loci for BP-lowering po-
tential. A more attractive approach is to link pharmacogenetic
interactions of GWAS signals with pleiotropic PheWAS results,
because this may reveal opportunities for drug repurposing and
Figure 3. Pharmacogenetic landscape of blood pressure. The Circos37 plot shows all the genome-wide association studieseidentified blood
pressure single-nucleotide polymorphisms (SNPs) and their putatively linked genes that show interaction with licensed antihypertensive drugs.
Monogenic genes are presented in red and GWAS SNP genes in dark grey. Chromosomes are represented as numbered bands. The coloured
square and circular markers indicate the number of antihypertensive drug classes that each gene interacts with. Drug-gene interactions were
obtained from the DrugBank32 and Comparative Toxicogenomics Database.33
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benefit from a drug. Table 2 summarises a set of pharmacogenes
that interact with GWAS BP genes and have BP lowering as a
documented side-effect. We also show the pleiotropic associa-
tions of these loci. Some of these drugs have failed trials for other
conditions and others have not been trialled for HTN. ET
antagonists and riociguat currently licensed for pulmonary
HTN show up as pharmacogenetic interactions with GWAS
loci for BP (EDNRA and GUCY1A2, respectively) and are
candidates for clinical trials for potential extension of their
current indication to essential HTN. Valproic acid showsmultiple interactions with a range of GWAS loci (HDAC9,
SCN2A, SCN10A), indicating that it may be a candidate for
repositioning. Nesiritide interacts with NPR3 and is currently
not licensed because it failed in a heart failure clinical trial.
PheWAS results indicate that pharmacogenes for valproic acid
are also associated with adiposity traits and heart rate, phar-
macogenes for ET antagonists are associated with CAD, and
nesiritide pharmacogene is associated with adiposity, basal
metabolic rate, height, lung function, and visceral fat traits.
These raise the possibility that new drug development or drug
repurposing needs to take into account multimorbid
Table 2. Pharmacologically active gene loci from genome-wide association studies (GWAS), their pleiotropic associations, and key drug-gene interactions with their indications and blood pressure
(BP) effects
GWAS locus Pleiotropic associations Antihypertensive license BP reduction as side-effect Effect on BP Therapeutic context/indication
ACE Nonpleiotropic Angiotensin-converting enzyme
inhibitors
YYYY Hypertension; Heart failure; Diabetes mellitus
nephropathy
Omapatrilat YY (Hypertension; Heart failuredfailed because
of adverse drug reactions)
ACVR2A Basophils, Eosinophils, Neutrophils,
Renal function, Urate
Sotatercept Y (Pulmonary hypertensiondphase II)
ADORA1 Nonpleiotropic Adenosine YY Supraventricular tachycardias
Pentoxifylline YY Peripheral vascular disease
ADRB1 Birth weight Bethanidine YY (Sympatholytic)
b-Blockers YYYY Hypertension; Angina; Arrhythmia; Heart
failure
Dobutamine YY Inotropic support; Cardiac stress testing
Amiodarone YY Arrhythmia
AKR1A1 Basophils, Granulocytes, Height,
Hematocrit, Hemoglobin,
Neutrophils, Platelet traits, RBC
traits, Reticulocytes, WBC
Tolrestat Y (Diabetes complicationsdfailed trials)
AKR1B10 Nonpleiotropic (Diabetes complicationsdfailed trials)
BCL2 Adiposity, BMI, BMR, CAD,
Glycemia, Hematocrit, RBC traits,
Reticulocytes, T2DM, Visceral.fat,
Weight
Docetaxel YY Solid tumours
CACNA1C Hematocrit, Hemoglobin, RBC traits Cinnarizine Y Menière disease
Spironolactone YYYY Hyperaldosteronism; Oedema; Heart failure;
Hypertension
Drotaverine YY Antispasmodic
Topiramate Y Epilepsy; Migraine
Calcium channel blockers YYYY Angina; Hypertension
CACNA1D Monogenic, Nonpleiotropic Cinnarizine Y Menière disease
Spironolactone YYYY Hyperaldosteronism; Oedema; Heart failure;
Hypertension
Calcium channel blockers YYYY Angina; Hypertension
CACNB2 Nonpleiotropic Spironolactone YYYY Hyperaldosteronism; Oedema; Heart failure;
Hypertension
Calcium channel blockers YYYY Angina; Hypertension
CHRM2 Heart rate Pizotifen YY Migraine
Disopyramide YY Arrhythmia
Cinnarizine Y Menière’s disease
Acetylcholine YY
Amitriptyline YY Depression; Neuropathic pain; Migraine
CSK Cholesterol, Granulocytes,
Hematocrit, Monocytes, Platelet
traits, RBC traits, Renal function
Dasatinib YY Chronic myeloid leukemia
CYP11B2 Height Spironolactone YYYY Hyperaldosteronism; Oedema; Heart failure;
Hypertension
DBH Nonpleiotropic Ascorbic acid Y Scurvy
DDAH1 Adiposity Esomeprazole Y Peptic ulcer disease
EDNRA CAD Ambrisentan YY Pulmonary hypertension
ESR1 Adiposity, Height Dobutamine YY Inotropic support; Cardiac stress testing
FGR BMI Dasatinib YY Chronic myeloid leukemia
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FRK Adiposity, Cholesterol, C-reactive
protein, Height, Low-density
lipoprotein
Dasatinib YY Chronic myeloid leukaemia
GUCY1A2 CAD Riociguat YY Pulmonary hypertension
HDAC7 Allergy, Asthma, Platelet traits,
Reticulocytes
Belinostat Y (T-cell lymphoma)
HDAC9 Adiposity, CAD, CVA
HDAC9 Adiposity, CAD, CVA Valproic acid Y Epilepsy; Bipolar disorder; Migraine
HRH1 Adiposity, BMD, Neoplasm Mirtazapine YY Depression
Pizotifen YY 5-HT, Muscarinic, H1, Alpha-adrenergic
antagonist
Dimenhydrinate Y Vertigo
Histamine YY
Cinnarizine Y Menière’s disease
Amitriptyline YY Depression; Neuropathic pain; Migraine
INSR Adiposity, High-density lipoprotein,
Height, Triglycerides, Urate,
Visceral.fat
Insulin Y Diabetes mellitus
KCNJ11 Adiposity, BMI, Glycemia, Height,
T2DM
Diazoxide YY Hypoglycemia
LIMK1 Lung function Dabrafenib YY Melanoma
MTHFR-NPPB CAD, RBC traits, Visceral fat Carvedilol Y Hypertension; Angina; Heart failure
NPR3 Adiposity, BMR, Height, Lung
function, Visceral fat, Weight
Nesiritide YY (Heart failuredfailed clinical trial)
PDE10A Nonpleiotropic Dipyridamole YY Adenosine deaminase and phosphodiesterase
Inhibitor
Papaverine YY (Antispasmodic)
PDE1A Adiposity, BMR, Weight Calcium channel blockers YYYY Angina; Hypertension
Bepridil YY Angina (withdrawn)
PDE3A CAD, Monogenic Amrinone Y Heart failure
PDE5A Basophils, CAD, Granulocytes, Platelet
traits, WBC
Dipyridamole YY Antiplatelet
Pentoxifylline YY Peripheral vascular disease
SCN10A Heart rate, Neoplasm Tetracaine Y Local anaesthetic
Lidocaine YY Local anaesthetic; Ventricular arrhythmia
Valproic acid Y Epilepsy; Bipolar disorder; Migraine
Brivaracetam Y Epilepsy
SCN2A Adiposity Zonisamide YY Epilepsy
Tetracaine Y Local anaesthetic
Valproic acid Y Epilepsy; Bipolar Disorder; Migraine
Brivaracetam Y Epilepsy
VEGFA Hematocrit, Hemoglobin, RBC traits,
Renal function, Urate
Carvedilol YYYY Hypertension; Angina; Heart failure
YES1 Nonpleiotropic Dasatinib YY Chronic myeloid leukaemia
All pleiotropic associations of GWAS BP single-nucleotide polymorphisms (SNPs) were extracted and categorised into groups of correlated traits. Some SNPs did not show any non-BP associations and were classified
as nonpleiotropic. The genes linked to GWAS SNPs were determined by proximity to the SNP and cardiovascular plausibility. Only 1 gene per loci was included. Drug-gene interactions were obtained from the
DrugBank and Comparative Toxicogenomics Database, and drug indications were obtained from the British National Formulary and Food and Drug Administration labelled indications.
BMI, body mass index; BMD, bone mineral density; BMR, basal metabolic rate; RBC, red blood cells; CAD, coronary artery disease; CVA, cerebrovascular accident; T2DM, type 2 diabetes mellitus; WBC, white
blood cells.
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Volume 36 2020associations for targeting treatment to the right subset of pa-
tients. Finally, instead of repurposing drugs, pleiotropic asso-
ciations open the possibility of multipurposing drugs, for
example, prioritising antidepressant drugs that additionally
lower BP for patients with hypertension and depression or
antiepileptics that also have BP-lowering potential for patients
who have both epilepsy and hypertension (Table 2).Polygenic Risk Scores
Because the genetic make-up of an individual is largely stable
from birth, genetic information has the potential to act as an
early risk predictor. Essential HTN is influenced by multiple
genetic variants with small individual effect sizes, so meaningful
risk prediction necessitates examining the aggregated impact of
these multiple variants. This is through calculation of a poly-
genic risk score (PRS), which is a mathematical aggregate of risk
conferred by all of the SNPs significantly associated with BP. It
is important to highlight that the risk information provided by
the PRS is different from the risk information from genetic
markers of monogenic disorders. The latter is a dichotomous
result (either high or low probability of disease), whereas the
former provides a wider range of probabilistic risk. In addition,
the rare variant genotype points to specific biological impact of
the variant, whereas the PRS is an amalgamation of numerous
small-effect variants across the genomewith no specific pathway
implicated. A PRS constructed to use of all of the significant
GWAS BP SNPs showed a significant association with stroke,
CAD, heart failure, and left ventricular mass, but not for kidney
function.34 This supports the established association between
HTN and cardiovascular outcomes and suggests that progres-
sion of renal damage due toHTNmay continue despite control
of HTN. Although there is considerable interest in the use of
PRS as a biomarker for early intervention, currently there is no
evidence for the clinical utility of PRS for intervention or disease
prevention. It is likely that PRS currently may have limited
utility because studies have been conducted in adults over the
age of 40 years where disease would already have been estab-
lished. However, PRS may have more value in identification of
younger at-risk individuals, whichmerits further study. There is
limited utility in personalisation of treatment or new drug
discovery through PRS, primarily because it is derived from an
amalgamation of all genetic variants and do not represent
unique pathways.Conclusions
Genomic studies have identified the largest set of SNPs for
BP compared with other complex traits. A proportion of these
may have translational potential, and the challenge is to
identify them. Pleiotropic associations may point to novel
underlying pathways or potentially subtypes of essential
HTN. Early translational application may be through drug
repositioning, followed by new drug development. PRSs look
attractive, but their clinical utility needs controlled studies,
and the potential ethical impacts of their widespread use
exacerbating health disparities need further assessment.35,36Funding Sources
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